Zhittya Genesis Medicine plans to launch what it is calling a “Compassionate Use Clinical Trial” of FGF-1, a biological compound aiming to stimulate new blood vessel growth in the brain, for people with mild-to-moderately severe Parkinson’s disease. Those interested in joining this open-label (no placebo group) pilot safety and early efficacy…
People who took part in remote, video-conducted clinical trials for Parkinson’s disease reported high levels of satisfaction and interest in participating in future studies with remote video visits, scientists report. Three such trials showed that recruitment was feasible and enrolled participants were geographically dispersed — from across dozens of…
Biogen and Denali Therapeutics are planning to launch two late-stage clinical trials to further evaluate the potential of their investigational oral therapy BIIB122/DNL151 in treating people with Parkinson’s disease. The Phase 3 and Phase 2b trials, expected to commence this year, will be led by Biogen and follow promising results…
Oral health affects life quality in adults with Parkinson’s, with oral health worsening with disease progression and resulting in a related greater decline in quality of life than is evident in adults of similar age without this disorder, a small study from the Netherlands reports. Motor difficulties impacting daily…
A commonly used measure of how motor symptoms are affecting daily life could also — for people in early stages of Parkinson’s disease — be taking into account the contribution of their non-motor symptoms, a study suggests. This is a likely reason for the discrepancies seen in evaluations made by patients…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded about $1.5 million in grants to AC Immune to support work into small molecules against two proteins that are key players in the neurodegeneration underlying Parkinson’s disease. The two grants will fund research into molecules able to enter the brain…
A protein present in the SARS-CoV-2 virus — the virus that causes COVID-19 — is able to interact with alpha-synuclein and speed the formation of amyloid fibrils, the toxic clumps that trigger nerve cells death and are a hallmark of Parkinson’s disease, a study has shown. “We show, in…
People with age-related macular degeneration, an eye disease that blurs central vision, may have a higher risk of developing Parkinson’s disease, a Taiwanese population‐based retrospective study suggests. The study, ‘Increased risk of Parkinson’s disease among patients with age-related macular degeneration,” was published in the journal BMC Ophthalmology. Age-related…
A new molecule — a peptide tweaked by scientists in the laboratory — has the potential to prevent the misfolding and toxic aggregation, or clumping, of misfolded alpha-synuclein protein, a hallmark of Parkinson’s disease, a study shows. This study, supported by funds from Alzheimer’s Research U.K., paves the…
Low oxygen levels during sleep and while exercising — resulting in poor endurance — are very common among Parkinson’s disease patients, despite dopaminergic treatment, an Italian study suggests. The findings indicate a need for combining motor and respiratory rehabilitation, particularly for patients with severe Parkinson’s, who show the lowest…
Get regular updates to your inbox.